aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From
By
Invalid Date
Share:
PharmEasy’s $5.6 billion value shrinks to $456 million, investor data shows
Indian online pharmacy PharmEasy’s valuation now stands at about $456 million, according to disclosures from its investor Janus Henderson, a 92% drop from its peak valuation of $5.6 billion. The British American global asset firm’s Global Research Fund values its holding of 12.9 million shares in PharmEasy at $766,043, according to its latest filing for the period ending September. The fund had originally spent $9.4 million to acquire these shares. The persistent low valuation comes despite Pha
Dec 26, 2024
PharmEasy investor cuts value of its stake drastically, implying new valuation of $456M
Indian online pharmacy PharmEasy is now being valued at about $456 million after its investor Janus Henderson said in a filing that it valued its stake of 12.9 million shares in the startup at $766,043. The asset manager’s Global Research Fund had originally spent $9.4 million to acquire these shares. This valuation is 92% less than PharmEasy’s all-time-high price tag of $5.6 billion. The persistent low valuation comes despite PharmEasy securing more than $200 million in fresh capital earlier
Dec 26, 2024
Elon Musk’s xAI lands $6B in new cash to fuel AI ambitions
Updated December 25, 12:21 p.m. Pacific: Added details of xAI’s valuation and Kingdom Holdings’ contribution. xAI, Elon Musk’s AI company, has raised $6 billion in a Series C financing round. The company announced this week that Andreessen Horowitz , Blackrock, Fidelity, Lightspeed, MGX, Morgan Stanley, OIA, QIA, Sequoia Capital, Valor Equity Partners, Vy Capital, Nvidia, AMD, and others participated. Kingdom Holdings, the Saudi conglomerate holding company, invested roughly $400 million in the
Dec 25, 2024
Don't miss our latest news and updates. Subscribe to the newsletter